NEW YORK, Nov. 21, 2016 /PRNewswire/ -- Taxotere lawsuits filed on behalf of cancer patients who allegedly experienced permanent hair loss following treatment with the chemotherapy agent have begun to move forward in a multidistrict litigation recently established in the U.S. District Court, Eastern District of Louisiana. Court records indicate that the proceeding's first Status Conference was convened on November 10th, followed by the issuance of two new Orders. The first, dated November 16th, stipulates that applications for Special Counsel for Settlement Negotiations be emailed to chambers no later than December 5, 2016. A second Order dated November 17th establishes the litigation's leadership structure, including Plaintiffs' Liaison Counsel and the Plaintiffs' Steering Committee. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm represents breast cancer patients and others who allegedly suffered permanent hair loss following Taxotere treatment. We are pleased that this litigation is moving forward, and will continue to monitor its progress for any developments relevant to our clients' cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere. Taxotere Hair Loss Allegations Taxotere (docetaxel) is marketed by Sanofi-Aventis, and was initially approved to treat breast cancer. Since being approved by the U.S. Food & Drug Administration (FDA) in 1996, the chemotherapy agent has also been cleared to treat head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. Last December, the Taxotere label was modified to note that cases of permanent alopecia had been reported among chemotherapy patients who had been treated with the medication.